The report entitled “US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)”, provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue,.
Complete report available at www.marketreportsonline.com/535595.html.
Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry.
- Agency -.
Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries are some of the key companies in the US tardive dyskinesia market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.
- Valeant Pharmaceuticals (Tertrabenazine)
- Neurocrine Biosciences (Valbenazine)
- Teva Pharmaceutical Industries (SD-809)
Psychosis is a condition described as loss of contact with reality. And the people suffering from this condition are called psychotics.
Some of the signs and symptom of psychosis are: difficulty in concentrating, depressed mood, sleeping too much or not enough, anxiety,. The two main types of psychiatric disorder related to tardive dyskinesia are Schizophrenia and Bipolar Disorder.
Involuntary movements of face, lips, tongue, extremities and trunk, is called tardive dyskinesia. This disease is caused by regular and long term intake of dopaminergic antagonist medications/ antipsychotics as a prescription for schizophrenia and bipolar disorder.
Some of the signs and symptoms of tardive dyskinesia are grimacing, tongue movements, lip smacking, lip puckering, pursing of the lips, excessive eye blinking,.
Report at www.marketreportsonline.com/contacts/535595.
Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botullinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809.
The US tardive dyskinesia market is expected to increase at a significant growth rate during the forecasted period (2016-2025). The US tardive dyskinesia market is supported by various growth drivers, such as increase in number of schizophrenia patients, rising bipolar disorder patients,.
Yet, the market faces certain challenges, such as, increased use of atypical antipsychotics, under-diagnosed market, side effects of drugs,.
For more information: